

- III. Claims 21-23 in part, and 24, drawn to a nucleic acid molecule encoding a neuroblastin polypeptide, as well as a process for producing a polypeptide in vivo, classified in class 514, subclass 44.
- IV. Claims 38-41, and 43-49, drawn to a method of administering truncated neuroblastin polypeptide in vivo, classified in class 514, subclass 2.
- V. Claims 42 and 50-53, drawn to a method of administering a truncated neuroblastin nucleic acid molecule in vivo, classified in class 514, subclass 44.
- VI. Claim 54, drawn to a kit comprising neuroblastin polypeptide and nucleic acid, classified in class 435, subclass 6.

ELECTION

In response to the outstanding Restriction Requirement, applicants elect Group I, claims 1-20, 35 and 36 drawn to truncated neuroblastin polypeptide, including that of SEQ ID NO:2, and a pharmaceutical composition, classified in class 530, subclass 350.. Applicants make this election without prejudice to their rights to traverse the restriction requirement with respect to non-elected groups.

CANCELLATION OF CLAIMS

Applicants kindly request the cancellation of claims 21-34 and 37-54, which are directed to non-elected subject matter. Applicants make the election of the Group I claims, and are requesting cancellation of the non-elected claims, expressly without waiver of their right to file for and obtain claims directed to the non-elected subject matter in divisional or continuing applications claiming priority and benefit herefrom under U.S.C. § 120.

CONCLUSION

Applicants request consideration and early allowance of the Group I claims.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Scott D. Miller, Reg. No. 43,803

Attorneys for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: February 3, 2003

NYC 255044v1



30623

PATENT TRADEMARK OFFICE